Document:

Exhibit 10.1

 

DIRECTOR AGREEMENT

 

This DIRECTOR AGREEMENT
is made as of [DATE] (the “Agreement”), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation
(the “Company”), and [DIRECTOR NAME], an individual with an address at [DIRECTOR ADDRESS] (the “Director”).

 

WHEREAS,
the Company has agreed to appoint the Director to its Board of Directors, and desires to enter into an agreement with the Director
with respect to such appointment; and

 

WHEREAS,
the Director is willing to accept such appointment and to serve the Company on the terms set forth herein and in accordance with
the provisions of this Agreement.

 

NOW, THEREFORE,
in consideration of the mutual covenants contained herein, the parties hereto agree as follows:

 

1.           Position.
Subject to the terms and provisions of this Agreement, the Company shall cause the Director to be appointed a Director of the Company
in the class of directors up for election at the 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”)
immediately upon the execution of this Agreement, and the Director hereby agrees to serve the Company in such position, upon the
terms and conditions hereinafter set forth, and in accordance with the duties imposed by Delaware law, the Company’s Amended
and Restated Certificate of Incorporation, the Company’s Amended and Restated By-Laws (the “Bylaws”) and
applicable stock exchange regulations, provided, however, that the Director’s continued service on the Board of Directors
of the Company (the “Board”) for any period following the 2016 Annual Meeting shall be subject to the nomination
of the Director for election by the Company’s stockholders by the Company’s Compensation, Nominating and Governance
Committee for such period, and the election of the Director by the stockholders of the Company.

 

2.           Duties.

 

(a)           During
the Directorship Term (as defined herein), the Director shall make reasonable business efforts to attend all Board meetings, serve
on appropriate committees as reasonably requested by the Board, make himself available to the Company at mutually convenient times
and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities,
and have the authority commensurate to such position.

 

(b)           The
Director will use his reasonable best efforts to promote the interests of the Company and devote such time to the Company’s
affairs as required to appropriately discharge his duties and legal obligations as a Director. Other than as set forth above, the
Director will not, without the prior notification to the Board, engage in any other business activity which could materially interfere
with the performance of his duties, services and responsibilities hereunder or which is in violation of the reasonable policies
established from time to time by the Company. At such time as the Board receives such notification, the Board may require the resignation
of the Director if it determines that such business activity does in fact materially interfere with the performance of the Director’s
duties, services and responsibilities hereunder.

 

3.           Compensation.

 

(a)           The
Company agrees to pay Director a fee of $50,000 as an annual retainer. Additionally, Director will receive a restricted stock award
under the Company’s 2014 Stock Incentive Plan of 28,000 shares of common stock, vesting on the first anniversary of the date
of grant. The Company and the Director acknowledge that under the Bylaws of the Company, the Board of Directors shall have authority
to fix the compensation of directors.

 

(b)           During
the Directorship Term, the Company shall reimburse the Director for all reasonable out-of-pocket expenses incurred by the Director
in attending any in-person meetings, provided that the Director complies with the generally applicable policies, practices and
procedures of the Company for submission of expense reports, receipts or similar documentation of such expenses. Any reimbursements
for allocated expenses (as compared to out-of-pocket expenses of the Director) must be approved in advance by the Company.

 

    	 	 	 

     

    

 

(c)           The
Company will maintain a customary director and officer liability insurance policy for all Board members and such policy will cover
Director to the same extent as other directors and officers covered under the policy.

 

(d)           The
Director’s status during the Directorship Term shall be that of an independent contractor and not, for any purpose, that
of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided
to the Director under this Section 3 shall be made or provided without withholding or deduction of any kind, and the Director shall
assume sole responsibility for discharging all tax or other obligations associated therewith.

 

4.           Directorship
Term. The “Directorship Term,” as used in this Agreement, shall mean the period commencing on the date hereof and
terminating on the earlier of the date of the next annual stockholders meeting and the earliest of the following to occur:

 

(a)           the
death of the Director;

 

(b)           the
termination of the Director from his membership on the Board by the mutual written agreement of the Company and the Director;

 

(c)           the
removal of the Director from the Board in accordance with the Bylaws and Delaware law; and

 

(d)           the
resignation by the Director from the Board.

 

5.           Director’s
Representations and Acknowledgment.

 

(a)           The
Director acknowledges and agrees that his position as member of the Board will result in him being deemed to be an “affiliate”
of the Company for purposes of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and
the regulations promulgated thereunder (collectively, the “Securities Laws”).

 

(b)           Other
than the Settlement Agreement, there is no arrangement, agreement or understanding between the Director and any other persons pursuant
to which the Director is being appointed to the Company’s Board of Directors.

 

(c)           The
Director represents to the Company that his execution and performance of this Agreement shall not be in violation of any agreement
or obligation (whether or not written) that he may have with or to any person or entity, including without limitation, any prior
or current employer. The Director hereby acknowledges and agrees that this Agreement (and any other agreement or obligation referred
to herein) shall be an obligation solely of the Company, and the Director shall have no recourse whatsoever against any officer,
director, employee, stockholder, representative or agent of the Company or any of their respective affiliates with regard to this
Agreement.

 

6.           Director
Covenants.

 

(a)           Unauthorized
Disclosure. The Director agrees and understands that in the Director’s position with the Company, the Director has been
and will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited
to, technical information, business and marketing plans, strategies, customer information, other information concerning the Company’s
products, services, promotions, development, financing, expansion plans, business policies and practices, and other forms of information
considered by the Company to be confidential, and proprietary and in the nature of trade secrets. The Director agrees that during
the Directorship Term and thereafter, subject to his fiduciary duties, the Director will keep such information confidential and
will not disclose such information, either directly or indirectly, to any third person or entity without the prior written consent
of the Company; provided, however, that (i) the Director shall have no such obligation to the extent such information (A) is or
becomes publicly known or generally known in the Company’s industry other than as a result of the Director’s breach
of his obligations hereunder, (B) is lawfully obtained from a source other than the Company that was not under, and did not impose,
an obligation of confidentiality with respect to such information; (C) is independently developed by Director or his Affiliates
without violating any of his obligations under this Agreement; and (D) is or becomes known by the Director other than through disclosure
by the Company in the course of the Directorship Term; and (ii) the Director may, after giving prior notice to the Company to the
extent practicable under the circumstances, disclose such information to the extent required by applicable laws or governmental
regulations or judicial or regulatory process. This confidentiality covenant has no geographical or territorial restriction. Upon
termination of the Directorship Term, the Director will promptly destroy all property, keys, notes, memoranda, writings, lists,
files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical data, other product
or document, and any summary or compilation of the foregoing, in whatever form, including, without limitation, in electronic form,
which has been produced by, received by or otherwise submitted to the Director in the course or otherwise as a result of the Director’s
position with the Company during or prior to the Directorship Term, provided that the Company shall retain such materials and make
them available to the Director if requested by him in connection with any litigation against the Director under circumstances in
which (i) the Director demonstrates to the reasonable satisfaction of the Company that the materials are necessary to his defense
in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction of the Company.

 

    	 	2	 

     

    

 

(b)           Company
Policies. Director acknowledges that he has received and reviewed a copy of the Company’s Code of Business Conduct and
Ethics, and its Supplemental Securities Trading Policy for Officers, Directors and Key Employees (the “Policies”),
and understands and agrees that he will strictly comply with all the requirements of the Policies during the Directorship Term
and so for so long thereafter as specifically required by the Policies, including without limitation the provisions thereof concerning
unauthorized communication of internal Company information to third parties, including responses to inquiries by the financial
press, investment analysts, investors, or other members of the financial community.

 

(c)           Non-Solicitation.
During the Directorship Term and for a period of two (2) years thereafter, the Director shall not interfere with the Company’s
relationship with, or endeavor to entice away from the Company, any person who, on the date of the termination of the Directorship
Term and/or at any time during the one year period prior to the termination of the Directorship Term, was an employee or customer
(including those reasonably expected to be a customer) of the Company or otherwise had a material business relationship with the
Company.

 

(d)           Remedies.
The Director agrees that any breach of the terms of this Section 6 could result in irreparable injury and damage to the Company
for which the Company could have no adequate remedy at law. The Director therefore also agrees that in the event of said breach
or any threat of breach, the Company shall be entitled to seek an immediate injunction and restraining order to prevent such breach
and/or threatened breach and/or continued breach by the Director and/or any and all of his affiliates, without having to prove
damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms
of this paragraph shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach
hereof, including, but not limited to, the recovery of damages from the Director. The Director acknowledges that the Company would
not have entered into this Agreement had the Director not agreed to the provisions of this Section 7.

 

(e)           Survival.
The provisions of this Section 6 shall survive any termination of the Directorship Term, and the existence of any claim or cause
of action by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense
to the enforcement by the Company of the covenants and agreements of this Section 6.

 

7.           Non-Waiver
of Rights. The failure to enforce at any time the provisions of this Agreement or to require at any time performance by the
other party hereto of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect
either the validity of this Agreement or any part hereof, or the right of either party hereto to enforce each and every provision
in accordance with its terms. No waiver by either party hereto of any breach by the other party hereto of any provision of this
Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions at that time or at any
prior or subsequent time.

 

8.           Notices.
Every notice relating to this Agreement shall be in writing and shall be given by personal delivery, overnight delivery or by
registered or certified mail, postage prepaid, return receipt requested; to:

 

    	 	3	 

     

    

 

If to the Company:

 

Navidea Biopharmaceuticals, Inc.

5600 Blazer Parkway

Suite 200

Dublin, OH 43017-7550

Attn: Jed A. Latkin, Interim Chief Operating Officer

 

 

with a copy (which shall not constitute notice) to:

 

Kevin W. Waite

Moomjian, Waite & Coleman, LLP

100 Jericho Quadrangle, Suite 208

Jericho, NY 11753

 

If to the Director:

 

	 	 
	 	 
	 	 

 

with a copy (which shall not constitute notice) to:

 

	 	 
	 	 
	 	 
	 	 

 

Either of the parties hereto may change their address for purposes
of notice hereunder by giving notice in writing to such other party pursuant to this Section 10.

 

9.           Binding
Effect/Assignment. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
heirs, executors, personal representatives, estates, successors (including, without limitation, by way of merger) and assigns,
as applicable. Notwithstanding the provisions of the immediately preceding sentence, neither the Director nor the Company shall
assign all or any portion of this Agreement without the prior written consent of the other party.

 

10.           Entire
Agreement. This Agreement sets forth the entire understanding of the parties hereto with respect to the subject matter hereof
and supersedes all prior agreements, written or oral, between them as to such subject matter.

 

11.           Severability.
If any provision of this Agreement, or any application thereof to any circumstances, is invalid, in whole or in part, such provision
or application shall to that extent be severable and shall not affect other provisions or applications of this Agreement.

 

12.           Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference
to the principles of conflict of laws. All actions and proceedings arising out of or relating to this Agreement shall be heard
and determined in the Court of Chancery of the State of Delaware and the parties hereto hereby consent to the jurisdiction of such
courts in any such action or proceeding; provided, however, that neither party hereto shall commence any such action or proceeding
unless prior thereto the parties have in good faith attempted to resolve the claim, dispute or cause of action which is the subject
of such action or proceeding through mediation by an independent third party.

 

13.           Modifications.
Neither this Agreement nor any provision hereof may be modified, altered, amended or waived except by an instrument in writing
duly signed by the party to be charged.

 

    	 	4	 

     

    

 

14.           Tense
and Headings. Whenever any words used herein are in the singular form, they shall be construed as though they were also used
in the plural form in all cases where they would so apply. The headings contained herein are solely for the purposes of reference,
are not part of this Agreement and shall not in any way affect the meaning or interpretation of this Agreement.

 

15.           Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together
shall constitute one and the same instrument.

 

IN WITNESS
WHEREOF, the Company has caused this Director Agreement to be executed by authority of its Board of Directors, and the Director
has hereunto set his hand, on the day and year first above written.

 

NAVIDEA BIOPHARMACEUTICALS, INC.

  

 

	By:	Jed A. Latkin	 	 
	 	Interim Chief Operating Officer	 	 

 

DIRECTOR

 

 

	 	 	 
	[DIRECTOR NAME]	 	 

 

 

 

 

 

    	 	5Exhibit
10.6

 

SUBSCRIPTION
AGREEMENT

 

This
Subscription Agreement (this “Agreement”), is made as of May 9, 2016 by and between WL Ross Holding Corp.
(the “Company”) and the undersigned subscriber (the “undersigned”) . In connection with
the proposed business combination between the Company and Nexeo Solutions Holdings, LLC (the “Nexeo Business
Combination”) pursuant to the Agreement and Plan of Merger, dated as of March 21, 2016, as may be amended from time
to time (the “Merger Agreement”), the Company is seeking commitments from certain of its existing
stockholders and other persons known to the Company to purchase shares of the Company’s common stock, par value $0.0001
per share (the “Shares”), for a purchase price of $10.00 per share, in a private placement.

 

1.     Subscription.
The undersigned hereby irrevocably subscribes for and agrees to purchase from the Company such number of Shares as is set forth
on the signature page of this Agreement on the terms provided for herein.

 

2.     Closing.
The closing of the sale of Shares contemplated hereby (the “Closing”) shall occur immediately prior to and
on the day of the closing of the Nexeo Business Combination. Upon not less than two (2) business days’ written notice from
(or on behalf of) the Company to the undersigned (the “Closing Notice”) that the Company reasonably expects
the closing of the Nexeo Business Combination to occur, the undersigned shall deliver as soon as reasonably practicable on the
expected date of the Closing specified in the Closing Notice (and prior to the closing of the Nexeo Business Combination) to an
account designated by the Company, the subscription amount for the Shares subscribed by wire transfer of United States dollars
in immediately available funds. On the day of the expected closing of the Nexeo Business Combination, the Company hereby covenants
that it shall notify the undersigned to withhold its wire of funds for the subscribed amount (or the Company will endeavor to
promptly return such funds wired by the undersigned that day) if it becomes readily apparent that the closing of the Nexeo Business
Combination will not occur that day. On the day immediately prior to the Closing, the Company shall deliver (or cause the delivery
of) the Shares in certificated form to a custodian designated by the undersigned. If the subscription is rejected in whole or
in part by the Company or if the Merger Agreement is terminated or cancelled prior to the Closing or prior to the closing of the
Nexeo Business Combination, any payment of the subscription amount made by the undersigned will be returned within one (1) business
day, without interest, by the Company, and any stock certificate(s) issued by the Company to the undersigned representing the
Shares will be returned promptly by the undersigned to the Company following the undersigned’s receipt of the returned subscription
payment amount.

 

3.     Conditions.
The closing of the sale of the Shares pursuant to this Agreement is conditioned upon (i) the Company obtaining the required approvals
from its stockholders for the proposals related to the Nexeo Business Combination (which include the issuance of shares under
this Agreement), (ii) if necessary prior to completing the Nexeo Business Combination, the Company obtaining the required approvals
from its stockholders for the proposals related to extending the Company’s corporate existence beyond June 11, 2016, (iii)
delivery of such stock certificate(s) to the address(es) designated by the undersigned in writing at least two (2) business days
prior to the expected date of the Closing with such stock certificate(s) dated as of the expected date of the Closing, (iv) the
satisfaction or waiver of all conditions precedent set forth in the Merger Agreement (other than those which may only be satisfied
at the closing of the Business Combination that may only occur following, or that the Company deems necessary or appropriate to
follow, the wire of funds by the undersigned pursuant to the terms hereof in order to close on the expected date of the Closing),
(v) the funds raised by the Company in the private placement of Shares, including from the Shares purchased by the undersigned
under this Agreement, equals or exceeds $41.6 million, (vi) receipt of the subscription amount for the Shares subscribed to by
the undersigned by wire transfer of United Stated dollars in immediately available funds pursuant to the terms hereof, (vii) execution
and delivery by the undersigned of the Investor Questionnaire and the Form W-9 described in Section 4 below, and (viii) the representations
and warranties of the undersigned set forth in such Investor Questionnaire are true and correct as of the date hereof and as of
the date of the Closing.

 

4.     Investor
Questionnaire; Form W-9. The undersigned has, concurrently with the execution and delivery of this Agreement, executed and
delivered the Investor Questionnaire and the Form W-9 in the forms attached hereto as Exhibit A and Exhibit B, respectively.
The representations and warranties of the undersigned set forth in the Investor Questionnaire shall be true and correct as of
the date hereof and as of the date of the Closing as if made on and as of such date. The undersigned agrees to promptly notify
the Company and provide it with the relevant updated information for any change in circumstances at any time on or prior to the
Closing.

 

     

     

    

 

5.     Expenses.
The undersigned shall pay all of its own expenses in connection with this Agreement and the transactions contemplated hereby.

 

6.     Registration
Rights. Promptly after the consummation of the Nexeo Business Combination (but no later than fifteen (15) business days thereafter),
the Company will (i) file with the SEC a registration statement registering (among other securities) the resale of the Shares
received by the undersigned in respect of the undersigned’s Shares acquired hereunder (the “Registration Statement”),
and (ii) use its reasonable best efforts to have the Registration Statement declared effective as soon as reasonably practicable
after the filing thereof and maintain the effectiveness of the Registration Statement until such time as the undersigned’s
Shares have been sold thereunder or can be sold in market transactions pursuant to Rule 144 under the Securities Act of 1933,
as amended, or any analogous or successor rule or regulation; provided, however, that (A) the Company shall not be required to
register or facilitate the resale of the undersigned’s Shares pursuant to any underwritten or marketed offering and (B)
the Company’s obligations to include such Shares in the Registration Statement are contingent upon the undersigned furnishing
in writing to the Company such information regarding the undersigned, the securities of the Company held by the undersigned and
the intended method of disposition of the Shares as shall be reasonably requested by the Company to effect the registration of
the Shares, and the undersigned shall execute such documents in connection with such registration as the Company may reasonably
request that are customary of a selling stockholder in similar situations, including, among other things, providing that the Company
shall be entitled to postpone and suspend the effectiveness or use of the Registration Statement during any customary blackout
or similar period. Subject to the undersigned’s compliance with this Agreement, the Company hereby expressly agrees to perform
the covenants contained in this Section 6.

 

7.     Company
Representations. The Company represents and warrants that:

 

(a)The
Company has been duly incorporated, is validly existing and is in good standing under the laws of the State of Delaware, with
corporate power and authority to own, lease and operate its properties and conduct its business as presently conducted.

 

(b)The
Agreement has been duly authorized, executed and delivered by the Company and constitutes a legal, valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by:
(i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws in effect that limit creditors’
rights generally; (ii) equitable limitations on the availability of specific remedies; (iii) principles of equity (regardless
of whether such enforcement is considered in a proceeding in law or in equity); and (iv) to the extent rights to indemnification
and contribution may be limited by federal securities laws.

 

(c)The
Shares have been duly authorized and, when issued and delivered to the undersigned against full payment therefor in accordance
with the terms of this Agreement, the Shares will be validly issued, fully paid and non-assessable and will not have been issued
in violation of or subject to any preemptive or similar rights created under the Company’s Certificate of Incorporation
or under the law of the State of Delaware. The issuance and sale of the Shares and the compliance by the Company with all of the
provisions of this Agreement and the consummation of the transactions herein will be done in accordance with the NASDAQ marketplace
rules.

 

(d)All
representations and warranties provided to the undersigned furnished by or on behalf of the Company taken as a whole, are true
and correct and do not contain any untrue statement of material fact or omit to state any material fact necessary in order to
make the statements made therein, in the light of the circumstances under which they were made, not misleading

 

8.     Trust
Account Waiver. The undersigned acknowledges that the Company is a blank check company formed for the purpose of effecting
a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or
more businesses. The undersigned further acknowledges that, as described in the final prospectus relating to the Company’s
initial public offering filed with the Securities and Exchange Commission on or about June 9, 2014 (the “Prospectus”),
substantially all of the Company’s assets consist of the cash proceeds of the Company’s initial public offering and
private placements of its securities and substantially all of those proceeds have been deposited into a trust account (the “Trust
Account”) for the benefit of the Company and its public stockholders. As described in the Prospectus, the funds held
from time to time in the Trust Account may only be released upon certain conditions. The undersigned hereby acknowledges and agrees
that, except with respect to shares of common stock of the Company owned by the undersigned acquired other than pursuant to this
Agreement, it has no right of set-off or any right, title, interest or claim of any kind (“Claim”) to, or to
any monies or other assets in, the Trust Account, and hereby irrevocably waives any Claim to, or to any monies or other assets
in, the Trust Account that it may have now or in the future. The undersigned acknowledges and agrees that the undersigned shall
not have any redemption rights with respect to the Shares pursuant to the Company’s Certificate of Incorporation in connection
with the stockholder proposals related to the Nexeo Business Combination or the extension of the Company’s corporate existence
beyond June 11, 2016, any subsequent liquidation of the Trust Account or the Company or otherwise. In the event the undersigned
has any Claim against the Company under this Agreement or otherwise, the undersigned shall pursue such Claim solely against the
Company and its assets held outside of the Trust Account and not against the Trust Account or any monies or other assets held
in the Trust Account.

 

     

     

    

  

9.     Governing
Law; Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of New York,
without regard to the principles of conflicts of law thereof that would require the application of the laws of any jurisdiction
other than New York. The undersigned consents to the non-exclusive jurisdiction of the federal courts whose districts encompass
any part of the City of New York or the state courts of the State of New York sitting in the City of New York in connection with
any dispute arising under this Agreement and hereby waives, to the maximum extent permitted by law, any objection, including any
objection based on forum non conveniens, to the bringing of any such proceeding in such jurisdictions.

 

10.     Specific
Performance. The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in
accordance with the terms hereof, and, accordingly, that the parties shall be entitled to an injunction or injunctions to prevent
breaches of this Agreement or to enforce specifically the performance of the terms and provisions hereof in any action brought
in the federal courts whose districts encompass any part of the City of New York or the state courts of the State of New York
sitting in the City of New York, without proof of actual damages or otherwise, in addition to any other remedy to which they are
entitled at law or in equity. Each of the parties hereby further waives (a) any defense in any action for specific performance
that a remedy at law would be adequate and (b) any requirement under any law to post security or a bond as a prerequisite
to obtaining equitable relief.

 

11.     WAIVER
OF JURY TRIAL. EACH OF THE PARTIES HERETO (ON BEHALF OF ITSELF AND ITS SUBSIDIARIES) HEREBY KNOWINGLY, INTENTIONALLY AND VOLUNTARILY
IRREVOCABLY WAIVES ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR
THE TRANSACTIONS CONTEMPLATED HEREBY.

 

12.     Assignment;
Third Party Beneficiaries. No party may assign any of its or his rights or delegate any of its or his obligations under this
Agreement without the prior written consent of the other parties. Subject to the preceding sentence, this Agreement shall be binding
upon and shall inure to the benefit of and be enforceable by the parties and their respective successors, including without limitation
any corporate successor by merger or otherwise. Nothing expressed or referred to in this Agreement will be construed to give any
person, other than the parties to this Agreement and their respective successors, any legal or equitable right, remedy or claim
under or with respect to this Agreement or any provision of this Agreement.

 

13.     Entire
Agreement. This Agreement along with the Investor Questionnaire attached hereto constitutes the entire agreement and supersedes
all prior agreements, understandings and representations and warranties, both written and oral, among the parties hereto with
respect to the subject matter hereof. Notwithstanding anything in this Agreement to the contrary, nothing herein shall be deemed
to modify, amend, or otherwise affect the rights and obligations of the Company set forth in the Merger Agreement.

 

     

     

    

  

14.     Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other authority
to be invalid, void, unenforceable or against its regulatory policy, the remainder of the terms, provisions, covenants and restrictions
of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and this Agreement
shall be reformed, construed and enforced in such jurisdiction such that the invalid, illegal or unenforceable provision or portion
thereof shall be interpreted to be only so broad as is enforceable.

 

15.     Counterparts.
This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement and shall
become effective when two or more counterparts have been signed by each of the parties and delivered to the other parties (including
by facsimile or via portable document format (.pdf)), it being understood that all parties need not sign the same counterpart.

 

16.     Expiration.
Except with respect to the Company’s obligation to return any subscription amount deposited pursuant to Section 2, this
Agreement shall terminate and be of no further force or effect and any stock certificate(s) issued representing the Shares shall
be cancelled, without any liability to the undersigned, if the Company issues a public announcement announcing the termination
of the Merger Agreement, and/or notifies the undersigned in writing that it has abandoned its plans to move forward with the Nexeo
Business Combination.

 

 

 

 

 

 

 

 

 

 

[Signature
page follows]

  

     

     

    

 

	 	UNDERSIGNED
	 	 	 
	 	Fidelity
    Select Portfolios: Chemical Portfolios
	 	 	 
	 	By:	/s/
    Stacie M. Smith
	 	Name: 	Stacie
    M. Smith
	 	Title: 	Authorized
    Signatory
	 	 	 
	 	Address:
    	245 Summer
    Street.
	 	 	 	Boston,
    MA 02210
	 	 	 
	 	Number
    of Shares Subscribed For: 1,220,000

 

 

	ACKNOWLEDGED
    AND AGREED:
	 	 	 
	WL
    ROSS HOLDING CORP.
	 	 	 
	By:	/s/
                                         Wilbur L. Ross, Jr.

	 
	Name: 	Wilbur L. Ross, Jr	 
	Title: 	Chairman	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
page to Subscription Agreement]

 

     

     

    

  

	 	UNDERSIGNED
	 	 	 
	 	Fidelity
    Advisor Series I: Fidelity Advisor Value Fund 
	 	 	 
	 	By: 	/s/
    Stacie M. Smith
	 	Name: 	Stacie
    M. Smith
	 	Title: 	Authorized
    Signatory
	 	 	 
	 	Address:
    	 	245
    Summer Street.
	 	 	 	Boston, MA
    02210
	 	 	 
	 	Number
    of Shares Subscribed For: 14,400

 

 

	ACKNOWLEDGED
    AND AGREED:
	 	 	 
	WL
    ROSS HOLDING CORP.
	 	 	 
	By:	/s/
                                         Wilbur L. Ross, Jr.

	 
	Name: 	Wilbur L. Ross, Jr	 
	Title: 	Chairman	 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
page to Subscription Agreement]

 

     

     

    

 

	 	UNDERSIGNED
	 	 	 
	 	Fidelity Capital
    Trust: Fidelity Value Fund
	 	 	 
	 	By: 	/s/
    Stacie M. Smith
	 	Name: 	Stacie
    M. Smith
	 	Title: 	Authorized
    Signatory
	 	 	 
	 	Address:
    	 	245
    Summer Street.
	 	 	 	Boston, MA
    02210
	 	 	 
	 	Number of Shares
    Subscribed For: 1,170,000

 

 

	ACKNOWLEDGED
    AND AGREED:
	 	 	 
	WL
    ROSS HOLDING CORP.
	 	 	 
	By:	/s/
                                         Wilbur L. Ross, Jr.

	 
	Name: 	Wilbur L. Ross, Jr	 
	Title: 	Chairman	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
page to Subscription Agreement]

 

     

     

    

 

	 	UNDERSIGNED
	 	 	 
	 	Fidelity Select
    Portfolios: Materials Portfolio
	 	 	 
	 	By: 	/s/
    Stacie M. Smith
	 	Name: 	Stacie
    M. Smith
	 	Title: 	Authorized
    Signatory
	 	 	 
	 	Address:
    	 	245
    Summer Street.
	 	 	 	Boston, MA
    02210
	 	 	 
	 	Number of Shares
    Subscribed For: 1,116,600

 

 

	ACKNOWLEDGED
    AND AGREED:
	 	 	 
	WL
    ROSS HOLDING CORP.
	 	 	 
	By:	/s/
                                         Wilbur L. Ross, Jr.

	 
	Name: 	Wilbur L. Ross, Jr	 
	Title: 	Chairman	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
page to Subscription Agreement]

 

     

     

    

 

	 	UNDERSIGNED
	 	 	 
	 	Fidelity Central
    Investment Portfolios LLC: Fidelity Materials Central Fund
	 	 	 
	 	By: 	/s/
    Stacie M. Smith
	 	Name: 	Stacie
    M. Smith
	 	Title: 	Authorized
    Signatory
	 	 	 
	 	Address:
    	 	245
    Summer Street.
	 	 	 	Boston, MA
    02210
	 	 	 
	 	Number of Shares
    Subscribed For: 300,000

 

 

	ACKNOWLEDGED
    AND AGREED:
	 	 	 
	WL
    ROSS HOLDING CORP.
	 	 	 
	By:	/s/
                                         Wilbur L. Ross, Jr.

	 
	Name: 	Wilbur L. Ross, Jr	 
	Title: 	Chairman	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
page to Subscription Agreement]

 

     

     

    

 

	 	UNDERSIGNED
	 	 	 
	 	Variable Insurance
    Products Fund IV: Materials Portfolio
	 	 	 
	 	By: 	/s/
    Stacie M. Smith
	 	Name: 	Stacie
    M. Smith
	 	Title: 	Authorized
    Signatory
	 	 	 
	 	Address:
    	 	245
    Summer Street.
	 	 	 	Boston, MA
    02210
	 	 	 
	 	Number of Shares
    Subscribed For: 39,000

 

 

	ACKNOWLEDGED
    AND AGREED:
	 	 	 
	WL
    ROSS HOLDING CORP.
	 	 	 
	By:	/s/
                                         Wilbur L. Ross, Jr.

	 
	Name: 	Wilbur L. Ross, Jr	 
	Title: 	Chairman	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature
page to Subscription Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]